Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: a review

TY - JOUR

T1 - Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion

T2 - a review

AU - Kårhus, Martin L

AU - Brønden, Andreas

AU - Sonne, David P

AU - Lauritsen, Tina Vilsbøll

AU - Knop, Filip Krag

N1 - This article is protected by copyright. All rights reserved.

PY - 2017/9

Y1 - 2017/9

N2 - Bile acids are amphipathic water-soluble steroid-based molecules best known for their important lipid-solubilizing role in the assimilation of fat. Recently, bile acids have emerged as metabolic integrators with glucose-lowering potential. Among a variety of gluco-metabolic effects, bile acids have been demonstrated to modulate the secretion of the gut-derived incretin hormone glucagon-like peptide-1 (GLP-1), possibly via the transmembrane receptor Takeda G-protein-coupled receptor 5 and the nuclear farnesoid X receptor, in intestinal L cells. The present article critically reviews current evidence connecting established glucose-lowering drugs to bile acid-induced GLP-1 secretion, and discusses whether bile acid-induced GLP-1 secretion may constitute a new basis for understanding how metformin, inhibitors of the apical sodium-dependent bile acids transporter, and bile acid sequestrants – old, new and neglected glucose-lowering drugs – improve glucose metabolism.

AB - Bile acids are amphipathic water-soluble steroid-based molecules best known for their important lipid-solubilizing role in the assimilation of fat. Recently, bile acids have emerged as metabolic integrators with glucose-lowering potential. Among a variety of gluco-metabolic effects, bile acids have been demonstrated to modulate the secretion of the gut-derived incretin hormone glucagon-like peptide-1 (GLP-1), possibly via the transmembrane receptor Takeda G-protein-coupled receptor 5 and the nuclear farnesoid X receptor, in intestinal L cells. The present article critically reviews current evidence connecting established glucose-lowering drugs to bile acid-induced GLP-1 secretion, and discusses whether bile acid-induced GLP-1 secretion may constitute a new basis for understanding how metformin, inhibitors of the apical sodium-dependent bile acids transporter, and bile acid sequestrants – old, new and neglected glucose-lowering drugs – improve glucose metabolism.

KW - Journal Article

KW - Review

U2 - 10.1111/dom.12946

DO - 10.1111/dom.12946

M3 - Review

C2 - 28304141

SN - 1462-8902

VL - 19

SP - 1214

EP - 1222

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 9

ER -